A New Tetracycline for Acne: The Role of Sarecycline
DOI:
https://doi.org/10.12775/QS.2025.42.61117Keywords
sarecycline, acne vulgaris, tetracyclineAbstract
INTRODUCTION AND OBJECTIVE
A common dermatological disorder that significantly affects both the physical appearance and mental well-being of patients is acne vulgaris. Its presence is frequently associated with reduced quality of life due to its chronic nature, visible lesions, and the risk of permanent scarring. The pathogenesis of acne is multifactorial and includes follicular hyperkeratinization, colonization of the skin by Cutibacterium acnes, inflammation, and overproduction of sebum. The purpose of this article is to present sarecycline, a third-generation tetracycline antibiotic approved by the United States Food and Drug Administration in 2018 for the treatment of moderate to severe acne vulgaris. The review summarizes current scientific findings regarding its clinical efficacy and safety profile.
MATERIALS AND METHODS
This article is based on a literature review concerning the therapeutic application of sarecycline in acne vulgaris. A comprehensive search was conducted using scientific databases including PubMed and Google Scholar, covering the period from 1999 to 2024. Keywords such as acne, tetracycline, and sarecycline were used to identify relevant studies.
CONCLUSION
Compared to traditional tetracyclines, sarecycline demonstrates limited activity against Gram-negative bacteria, which helps reduce the incidence of gastrointestinal side effects. Due to its favorable efficacy and safety profile, it is considered a valuable treatment option, especially for patients requiring long-term antibiotic therapy. Sarecycline has the potential to redefine established treatment paradigms in the management of acne vulgaris.
References
1. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41(4):577–580. doi:10.1016/S0190-9622(99)80056-5.
2. Samuels DV, Rosenthal R, Lin R, Chaudhari S, Natsuaki MN. Acne vulgaris and risk of depression and anxiety: A meta-analytic review. J Am Acad Dermatol. 2020;83(2):532-541. doi:10.1016/j.jaad.2020.02.040.
3. Del Rosso JQ, Kircik LH, Stein Gold L, Thiboutot D, Gallo R, Granstein RD, Webster G, Leyden JJ, Bhatia N, Zeichner JA, Baldwin H, Eichenfield LF, Zaenglein AL, Rosen T, Alexis AF, Bikowski J, Cohen DE, Draelos ZD, Elewski BE, Feldman SR, Gold LS, Jorizzo JL, Keri JE, Kligman AM, Krakowski AC, Mancini AJ, Pariser DM, Schlosser BJ, Shalita AR, Siegfried EC, Silverberg NB, Swanson NA, Taylor SC, Torok HM, Weiss JS, Woolery-Lloyd H. The role of oral antibiotics in the management of acne vulgaris: A status report and overview. J Cosmet Dermatol. 2020;19(12):3189–3197. doi:10.1111/jocd.13753.
4. Meixiong J, Ricco C, Vasavda C, Ho BK. Diet and acne: A systematic review. JAAD Int. 2022;7:95-112. doi:10.1016/j.jdin.2022.02.012.
5. Ryguła I, Pikiewicz W, Kaminiów K. Impact of diet and nutrition in patients with acne vulgaris. Nutrients. 2024;16(10):1476. doi:10.3390/nu16101476.
6. Alexis A, Tan J, Rocha M, Kerob D, Demessant AL, Ly F, Wu Y, Sachdev M, Kurokawa I. Is acne the same around the world? J Clin Aesthet Dermatol. 2024;17(9):16–22. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11386966/
7. Adebamowo CA, Spiegelman D, Berkey CS, Danby FW, Rockett HH, Colditz GA, Willett WC, Holmes MD. Milk consumption and acne in teenaged boys. J Am Acad Dermatol. 2008;58(5):787–793. doi: 10.1016/j.jaad.2007.08.049.
8. Bond P, Smit DL, de Ronde W. Anabolic–androgenic steroids: How do they work and what are the risks? Front Endocrinol (Lausanne). 2022;13:1059473. doi:10.3389/fendo.2022.1059473.
9. Asadi-Pooya AA, Rostaminejad M, Zeraatpisheh Z, Mirzaei Damabi N. Cosmetic adverse effects of antiseizure medications; A systematic review. Seizure. 2021;91:9-21. doi:10.1016/j.seizure.2021.05.010.
10. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15. doi:10.1016/j.jaad.2005.01.010.
11. Kazandjieva J, Tsankov N. Drug-induced acne. Clin Dermatol. 2017;35(2):156–62. doi:10.1016/j.clindermatol.2016.10.007.
12. Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019;14(14):1235–1242. doi:10.2217/fmb-2019-0199.
13. Lomakin IB, Devarkar SC, Patel S, Grada A, Bunick CG. Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism. Nucleic Acids Res. 2023;51(6):2915–2930. doi:10.1093/nar/gkad103.
14. Adjei S, Miller AC, Temiz LA, Tyring SK. Sarecycline: A Narrow-Spectrum Antibiotic. Skin Therapy Lett. 2022;27(3). Available from: https://www.skintherapyletter.com/acne/sarecycline-narrow-spectrum-antibiotic/
15. Batool Z, Lomakin IB, Polikanov YS, Bunick CG. Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome. Proc Natl Acad Sci U S A. 2020;117(34):20530–20537. doi:10.1073/pnas.2008671117.
16. Jung E, Gademann K. Clinically Approved Antibiotics from 2010 to 2022. Chimia (Aarau). 2023;77(3):230–235. doi:10.2533/chimia.2023.230.
17. Rusu A, Buta EL. The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. Pharmaceutics. 2021;13(12):2085. doi:10.3390/pharmaceutics13122085.
18. Tao RE, Prajapati S, Pixley JN, Grada A, Feldman SR. Oral Tetracycline-Class Drugs in Dermatology: Impact of Food Intake on Absorption and Efficacy. Antibiotics (Basel). 2023;12(7):1152. doi:10.3390/antibiotics12071152.
19. Rupert J, Hughes P. Sarecycline (Seysara) for the Treatment of Acne. Am Fam Physician. 2020;102(4):245–246. Available from: https://www.aafp.org/pubs/afp/issues/2020/0815/p245.html .
20. Grada A, Del Rosso JQ, Graber E, Bunick CG, Stein Gold L, Moore AY, Baldwin H, Obagi Z, Damiani G, Carrothers T, McNamee B, Hanze E. Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy. Dermatol Ther. 2022;35(3):e15275. doi:10.1111/dth.15275.
21. Abadie RB, Keller CL, Jones NT, Mayeux EL, Klapper RJ, Anderson L, Kaye AM, Ahmadzadeh S, Varrassi G, Shekoohi S, Kaye AD. Review of Teratogenic Effects of Leflunomide, Accutane, Thalidomide, Warfarin, Tetracycline, and Angiotensin-Converting Enzyme Inhibitors. Cureus. 2023;15(12):e50465. doi:10.7759/cureus.50465.
22. Smilack JD. Tetracyclines. Mayo Clin Proc. 1999;74(7):727–729. doi:10.4065/74.7.727.
23. Sachdeva P, Patel BG, Patel BK. Drug use in pregnancy; a point to ponder! Indian J Pharm Sci. 2009 Jan-Feb;71(1):1–7. doi: 10.4103/0250-474X.51941.
24. Moura IB, Grada A, Spittal W, Clark E, Ewin D, Altringham J, Fumero E, Wilcox MH, Buckley AM. Profiling the Effects of Systemic Antibiotics for Acne, Including the Narrow-Spectrum Antibiotic Sarecycline, on the Human Gut Microbiota. Front Microbiol. 2022;13:901911. doi:10.3389/fmicb.2022.901911.
25. Bunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, Grada A. Antibacterial mechanisms and efficacy of sarecycline in animal models of infection and inflammation. Antibiotics (Basel). 2021;10(4):439. doi:10.3390/antibiotics10040439.
26. Moore AY, Del Rosso J, Johnson JL, Grada A. Sarecycline: A Review of Preclinical and Clinical Evidence. Clin Cosmet Investig Dermatol. 2020;13:553–560. doi:10.2147/CCID.S190473.
27. Deeks ED. Sarecycline: First Global Approval. Drugs. 2019;79(3):325–329. doi:10.1007/s40265-019-1053-4.
28. Kim YS, Kim HS. Tetracyclines Revisited: Tetracyclines in the Field of Dermatology. Dermatology. 2024;240(5-6):844–858. doi:10.1159/000542006.
29. Warner AJ, Hathaway-Schrader JD, Lubker R, Davies C, Novince CM. Tetracyclines and bone: unclear actions with potentially lasting effects. Bone. 2022;159:116377. doi:10.1016/j.bone.2022.116377.
30. Xiong CY, Yang YM, Zhou Y, He TS, Luo XW, Wang J, Mao CX. Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database. Expert Opin Drug Saf. 2024;23(8):1–9. doi:10.1080/14740338.2024.2392
31. Swallow MA, Fan R, Cohen JM, Bunick CG. Antibiotic resistance risk with oral tetracycline treatment of acne vulgaris. Antibiotics (Basel). 2022;11(8):1032. doi:10.3390/antibiotics11081032.
32. Grada A, Del Rosso JQ, Moore AY, Stein Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem RJ, Tanaka SK, Bunick CG. Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity. Front Med (Lausanne). 2022;9:1033980. doi:10.3389/fmed.2022.1033980.
33. Baldwin H. Oral Antibiotic Treatment Options for Acne Vulgaris. J Clin Aesthet Dermatol. 2020;13(9):26–32. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577330/ .
34. Grada A, Ghannoum MA, Bunick CG. Sarecycline demonstrates clinical effectiveness against staphylococcal infections and inflammatory dermatoses: Evidence for improving antibiotic stewardship in dermatology. Antibiotics (Basel). 2022;11(6):722. doi:10.3390/antibiotics11060722.
35. Moore AY, Hurley K, Moore SA, Moore L, Zago I. Effect of Sarecycline on the Acne Symptom and Impact Scale and Concerns in Moderate-to-Severe Truncal Acne in Open-Label Pilot Study. Antibiotics (Basel). 2023;12(1):94. doi: 10.3390/antibiotics12010094.
36. Moore AY, Hurley K, Moore SA. A post hoc analysis of efficacy data on sarecycline in Hispanics with acne from two phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trials. Antibiotics. 2023;12(1):89. doi:10.3390/antibiotics12010089.
37. Goetze S, Hiernickel C, Elsner P. Phototoxicity of doxycycline: a systematic review on clinical manifestations, frequency, cofactors, and prevention. Skin Pharmacol Physiol. 2017;30(2):76–80. doi:10.1159/000455849.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Antonina Witkowska, Barbara Anna Zapalska, Julia Piotrowska, Adrianna Witkowska, Adrianna Domańska, Aleksandra Łubińska-Kowalska , Agata Żak-Gontarz, Aleksandra Minda, Justyna Janikowska, Krzysztof Julian Długosz, Monika Wendland, Artur Galus
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 262
Number of citations: 0
